Literature DB >> 26151398

My, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A!

Elizabeth G Grubbs1, Robert F Gagel1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26151398      PMCID: PMC5393525          DOI: 10.1210/jc.2015-2516

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  20 in total

1.  Clinically useful calcitonin assays.

Authors:  W B Carter; H Heath
Journal:  Trends Endocrinol Metab       Date:  1990 Jul-Aug       Impact factor: 12.015

2.  Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.

Authors:  Linwah Yip; Gilbert J Cote; Suzanne E Shapiro; Gregory D Ayers; Cynthia E Herzog; Rena V Sellin; Steven I Sherman; Robert F Gagel; Jeffrey E Lee; Douglas B Evans
Journal:  Arch Surg       Date:  2003-04

3.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

Review 4.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  Therapeutic Effectiveness of Screening for Multiple Endocrine Neoplasia Type 2A.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2015-05-06       Impact factor: 5.958

6.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 7.  Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.

Authors:  Karin Frank-Raue; Susanne Rondot; Friedhelm Raue
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

8.  A REVIEW OF 17 CASES OF CARCINOMA OF THE THYROID AND PHAEOCHROMOCYTOMA.

Authors:  E D WILLIAMS
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

9.  Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

Authors:  Nishant Agrawal; Yuchen Jiao; Mark Sausen; Rebecca Leary; Chetan Bettegowda; Nicholas J Roberts; Sheetal Bhan; Allen S Ho; Zubair Khan; Justin Bishop; William H Westra; Laura D Wood; Ralph H Hruban; Ralph P Tufano; Bruce Robinson; Henning Dralle; Sergio P A Toledo; Rodrigo A Toledo; Luc G T Morris; Ronald A Ghossein; James A Fagin; Timothy A Chan; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Barry D Nelkin; Douglas W Ball
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

10.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Authors:  Francesca Carlomagno; Donata Vitagliano; Teresa Guida; Fortunato Ciardiello; Giampaolo Tortora; Giancarlo Vecchio; Anderson J Ryan; Gabriella Fontanini; Alfredo Fusco; Massimo Santoro
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

View more
  1 in total

1.  Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.

Authors:  Rachel K Voss; Lei Feng; Jeffrey E Lee; Nancy D Perrier; Paul H Graham; Samuel M Hyde; Frances Nieves-Munoz; Maria E Cabanillas; Steven G Waguespack; Gilbert J Cote; Robert F Gagel; Elizabeth G Grubbs
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.